Preview

Eli Lilly &Company

Better Essays
Open Document
Open Document
2203 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Eli Lilly &Company
Case 3 :Eli Lilly &company

Question: To continue generating the returns enjoyed by the industry over the past decade, pharmaceutical companies would be forced to rethink how they identify and exploit opportunities to gain a competitive edge in an increasingly complex market ?

In my opinion if a Pharmaceutical company aims to continue generating the returns and gain competitive edge , should conduct Pharmaceutical Industry Analysis which will help to find out opportunities and then should try to match them with its Strengths and finally achieve to competitive benefits through new strategy formulations, so first I would like to bring a summary of strategic issues which Eli Lilly is face to them, second I will describe Eli Lilli external condition, through industry analysis and porters 5 forces ( to analyze external environment), third I try to bring SWOT analysis and SWOT matrix and finally according to the Opportunities, I try to bring some recommendations for strategy formulation which will place Lilly in a much stronger position to achieve and maintain sustainable competitive advantage in the dynamic competitive international pharmaceutical market.

Summary of Key Strategic Issues which Eli Lilli face to them

1)In Eli Lilli Imbalanced portfolio and lagging international sales was the consequence of its dependence on just a few key products. This type of a strategy with a focus on neuroscience drugs such Zyprexa was not well suited to the more cost conscious international regions whose their focus was treatment of disease.

2) Other factors that played against Eli Lilli were the regulations in non-US developed countries on pricing and payment programs for pharmaceutical drugs through national health insurance programs. Due to this fact, Lilly wouldn't have earned as high of a profit margin on its blockbuster drugs, Prozac and Zyprexa, in Europe and Japan as it did in the less price-conscious U.S. market.

3)Eli Lilly's recent decline in

You May Also Find These Documents Helpful

  • Powerful Essays

    Teva Pharmacuetical

    • 2882 Words
    • 12 Pages

    The first strategic issue that faces the firm lies at the very root of pharmaceuticals, the decision to be either an innovative or generic pharmaceutical company. Thus…

    • 2882 Words
    • 12 Pages
    Powerful Essays
  • Better Essays

    Pharmanet-i3, a subsidiary of inVentive Health, is a world leading clinical research organization committed to the advancement of health around the world. The mission of Pharmanet-i3 is to be a strategic partner to companies that develop therapeutic drugs, and aim to bring drugs to the public that treat disease and improve the quality of life. The company will operate within the industry’s highest quality standards with uncompromising integrity, ethics, and respect for employees, study participants, the environment, and the communities in which the employees live and work. Shareholders can expect superior returns through the implementation of a successful growth strategy (Pharmanet-I3, n.d.).…

    • 1342 Words
    • 6 Pages
    Better Essays
  • Good Essays

    Eli Lilly

    • 659 Words
    • 3 Pages

    What is a "heavyweight project team" and how does it differ from the traditional approach used for organizing projects at Eli Lilly?…

    • 659 Words
    • 3 Pages
    Good Essays
  • Powerful Essays

    Analysis of the Medicines Company case revealed several critical aspects that need to be addressed. The pharmaceutical industry can be very profitable, but is also very risky. As described in the case, bringing a new drug to market is a costly and lengthy process requiring an average of 10 years. Big Pharmaceutical companies struggle to keep upcoming drugs in their pipeline to provide revenue when existing drugs come off patent and are replaced by generic compounds. With 1 in 4000 compounds making it to market, there is significant risk of failure that can be reduced by having many compounds in development. Additionally, a drug company's reputation can easily be tarnished by safety issues with a compound, dramatically affecting their sales.…

    • 2114 Words
    • 7 Pages
    Powerful Essays
  • Satisfactory Essays

    The flexibility in price mark-ups through the OECD countries. US pharmaceutical manufacturers have received at least 60% of sales profits.…

    • 512 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    Through the late 80's to early 90's, Merck was able to boast profits and sales through biochemistry drugs that were seen as breakthrough drugs in this new market. With this sudden boom competitors started to take notice and emulate Merck's business model. This success also brought up a number of questions within Merck as a company; mainly how was Merck going to keep up with its numbers and keep pumping new drugs into the market. By assessing some strengths, weaknesses, opportunities and threats (SWOT Analysis) of the firm itself and offering some recommendations of how Merck may be able to conquer this challenge, you will be able to conclude that the success of Merck as a company relies heavily on its management and how they adapt the business model that is already in place to that of the ever-changing pharmaceutical industry.…

    • 2963 Words
    • 12 Pages
    Powerful Essays
  • Good Essays

    An issue with the distribution of drugs is that it is more profitable for drug companies to sell the drugs in MEDC’s than LEDC’s. An example of this would be GlaxoSmithKline, as they mainly sell their products in MEDC’s, but in many cases, the countries with…

    • 381 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.…

    • 1398 Words
    • 6 Pages
    Powerful Essays
  • Powerful Essays

    Eli Lilly

    • 2933 Words
    • 12 Pages

    This case outlines the difficulty faced by Eli Lilly, a pharmaceutical company’s decision as to whether they should develop a lead migraine compound. This decision is faced by the Project Manager Bianca Sharma and she has to make recommendations in the PTAC meeting. A number of things have to be considered like- time to market, diversity of leads, traditional or combinatorial chemistry etc. which is unique to the pharmaceutical industry. Other factors which might not be unique to this industry but still has to be considered in this analysis are- intellectual property (IP), funding for clinical trials, reliability of the product and process, alternatives to the product, firm’s short term and long term strategy, market conditions etc.…

    • 2933 Words
    • 12 Pages
    Powerful Essays
  • Powerful Essays

    Pfizer Analysis

    • 1396 Words
    • 6 Pages

    Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well as the opportunities and threats that it faces, its strategic priorities and the acquisition strategy that it might follow.…

    • 1396 Words
    • 6 Pages
    Powerful Essays
  • Better Essays

    Merck & Co

    • 1066 Words
    • 5 Pages

    1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop a new drug?…

    • 1066 Words
    • 5 Pages
    Better Essays
  • Good Essays

    Nova is considering the main competitor for Eli Lilly. But both two companies put up similar product into market. They try to put out the newest product in order to attract more customers and gain more profit from it. But does the customer really need those newest products. It becomes the question between should the product be consumers-demand trajectory or technology-performance trajectory. In…

    • 817 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Eli Lilly & Company

    • 688 Words
    • 3 Pages

    Eli Lilly and Company is one of the world’s top pharmaceutical companies, and is located in the United States. Their main competitors in the United States are Johnson and Johnson Corporation and Pfizer Incorporated. All three companies specialize in the manufacturing of pharmaceutical and medical products.…

    • 688 Words
    • 3 Pages
    Good Essays
  • Good Essays

    eli lilly

    • 1378 Words
    • 6 Pages

    What is a "heavyweight project team" and how does it differ from the traditional approach used for organizing development projects at Eli Lilly? This consists of two issues. First, is an evaluation of the changes taking place in the pharmaceutical industry and what it is that caused Lilly to feel compelled to try the heavyweight development approach on two of its drug development projects? Second, is understanding the essence of the heavyweight team approach, particularly as it has been used by Lilly?…

    • 1378 Words
    • 6 Pages
    Good Essays
  • Powerful Essays

    Key Learnings in a post graduate PhD course are truly in the eye of the beholder, or in this case, in the eye of the learner. A great deal of outside research was completed to support as well as contradict the findings of authors James C. Collins and Jerry I. Porras of Built to Last, and Jerald Greenberg in Managing Behaviors in Organizations. When the dust had settled the topics that provided the greatest opportunity to learn as per this PhD student were: Who or What is Visionary, Culture of High Achieving Organizations, Creativity and Innovation of High Achieving Organizations, The Metaphor of Clock Building, Management Dilemma – Internally or Externally, and The Quest for Leadership. The challenge that then entailed was to form these key topics into a paper with enough cohesiveness in it to make its reading informative, and hopefully educational. Enjoy.…

    • 2339 Words
    • 9 Pages
    Powerful Essays